Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer,Journal of Advanced Research

当前位置： X-MOL 学术 › J. Adv. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer
Journal of Advanced Research ( IF 11.4 ) Pub Date : 2022-11-06 , DOI: 10.1016/j.jare.2022.10.019
Yanan Cheng ₁ , Dechao Bu ₂ , Qiaoling Zhang ₁ , Rebecca Sun ₃ , Stephen Lyle ₃ , Gang Zhao ₄ , Li Dong ₁ , Hui Li ₄ , Yi Zhao ₂ , Jinpu Yu ₁ , Xishan Hao ₁

Affiliation

Introduction

Gastric cancer (GC)is the third leading cause of cancer-related deaths in China and immunotherapy emerging as a revolutionary treatment for GC recently. Tumor mutational burden (TMB) is a predictive biomarker of immunotherapy in multiple cancers. However, the prognostic significance and subtype of TMB in GC is not fully understood.

Objectives

This study aims to evaluate the prognostic value of TMB in Chinese GC and further classify TMB-high GC (GC^TMB-H) patients combing with mutational signatures.

Methods

Genomic profiling of 435 cancer-gene panel was performed using 206 GC samples from Chinese people. Actionable genetic alterations were compared across all the samples to generate actionable subtyping. The prognostic value of TMB in Chinese GC was evaluated. Mutational signatures were analyzed on TMB-H subtype to stratify the prognosis of TMB. Transcriptomic analysis was applied to compare the distributed immunocytes among different subtypes.

Results

88.3% (182/206) of GC samples had at least one mutation, while 45.1% (93/206) had at least one somatic copy number alteration (SCNA). 29.6% (61/206) of GC samples were TMB-H, including 13 MSI-H and 48 MSS tumors. According to distinct genetic alteration profiles of 69 actionable genes, we classified GC samples into eight molecular subtypes, including TMB-H, ERBB2 amplified, ATM mutated, BRCA2 mutated, CDKN2A/B deleted, PI3KCA mutated, KRAS mutated, and less-mutated subtype. TMB-H subtype presented a remarkable immune-activated phenotype as determined by transcriptomic analysis that was further validated in the TCGA GC cohort. GC^TMB-H patients exhibited significantly better survival (P = 0.047). But Signature 1-high GC^TMB-H patients had relatively worse prognosis (P = 0.0209, HR = 2.571) than Signature 1-low GC^TMB-H patients from Chinese GC cohort, also validated in TCGA GC cohort, presenting highly activated carbohydrate, fatty acid or lipid metabolism.